MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.71
Index: ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.765

19 Apr
2024

-0.010

OPEN

$0.77

-1.29%

HIGH

$0.80

6,472,845

LOW

$0.76

TARGET
$1.40 83.0% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 9.4 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-15.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.2 M
Book Value Per Share xxxxxxxxxxxxxxx87.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-103.0 M
Net Profit Margin xxxxxxxxxxxxxxx-1,091.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-16.49 %
Return on Invested Capital xxxxxxxxxxxxxxx-13.68 %
Return on Assets xxxxxxxxxxxxxxx-11.61 %
Return on Equity xxxxxxxxxxxxxxx-16.49 %
Return on Total Capital xxxxxxxxxxxxxxx-11.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-103.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx15 M
Long Term Debt xxxxxxxxxxxxxxx160 M
Total Debt xxxxxxxxxxxxxxx175 M
Goodwill - Gross xxxxxxxxxxxxxxx202 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx107 M
Price To Book Value xxxxxxxxxxxxxxx1.22

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx4.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx41 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx78 M
Research & Development xxxxxxxxxxxxxxx40 M
Investments - Total xxxxxxxxxxxxxxx3 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

08/04/2024

1

Buy

$1.40

83.01%

A carefully worded notice has come from the FDA, says Bell Potter, to notify Mesoblast that available clinical data appears sufficient to support resubmission of the Biological Licence Application (BLA) for Remestemcel.

While to date the absence of a second multicentre study has been a key factor prevented the BLA approval for Remestemcel, the notice suggests data from the single multicentre trial, alongside confirmatory data from the access program, may be sufficient. 

The broker estimates approval around mid-August.

The Buy rating is retained and the target price increases to $1.40 from 58 cents.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -9.44 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -10.81 cents.
Access Stockbroker Research History >

MSB STOCK CHART

FNArena News on MSB

1
The Short Report – 21 Dec 2023

Dec 21 2023 - Weekly Reports
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Weekly Ratings, Targets, Forecast Changes – 22-09-23

Sep 25 2023 - Weekly Reports
4
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
5
FNArena Corporate Results Monitor – 04-09-2023

Sep 04 2023 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
2
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
3
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
4
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
5
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
6
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
7
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
8
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
9
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
10
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps